Stock ENTX ENTERA BIO LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News Entera Bio Ltd.

Equities

ENTX

IL0011429839

Market Closed - Nasdaq
Other stock markets
 01:00:00 2024-07-03 pm EDT 		5-day change 1st Jan Change
1.64 USD -4.09% Intraday chart for Entera Bio Ltd. -12.30% +173.33%
May. 15 Entera Bio Appoints Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member CI
May. 13 Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets for the Treatment of Hypoparathyroidism at ENDO 2024 CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Entera Bio Reports Phase 1 Clinical Data of First-in-Class, Oral PTH(1-34) Peptide Candidate (EB612) for Patients with Hypoparathyroidism at ENDO 2024
AQ
Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member
AQ
Entera Bio Appoints Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member
CI
Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024
AQ
Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets for the Treatment of Hypoparathyroidism at ENDO 2024
CI
Entera Bio Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Entera Bio Reports Q1 2024 Financial Results and Provides Business Updates
AQ
Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research
AQ
Entera Bio Ltd. Announces Publication of Oral PTH(1-34) Peptide Tablets Phase 2 Trial Data in the Journal of Bone and Mineral Research
CI
Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months
AQ
Entera Bio Ltd. Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs Is Expected Within 10 Months
CI
Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome
AQ
Entera Bio Announces Robust Pharmacokinetic Data for First-In-Class Oral Glp-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome
CI
Entera Bio Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates
AQ
Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement
AQ
Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
AQ
Top Premarket Gainers
MT
Top Premarket Gainers
MT
Entera Bio Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ENTX Stock
  4. News Entera Bio Ltd.